{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:03:35Z","timestamp":1790715815034,"version":"4.1.0"},"reference-count":252,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473861"],"award-info":[{"award-number":["82473861"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>mRNA vaccines have become a clinically validated vaccine platform, as demonstrated by the success of COVID-19 vaccines such as Comirnaty and Spikevax, owing to their rapid design, manufacturing scalability, and capacity to induce in situ antigen expression. A key factor underlying this success is the lipid nanoparticle (LNP) delivery system, which protects mRNA from degradation and promotes efficient cellular uptake and cytoplasmic delivery, thereby enabling the full potential of mRNA technology. The continued advancement of mRNA-LNP vaccines requires integrated optimization of mRNA design, LNP composition, and delivery strategies to achieve improved stability, efficient intracellular delivery, and balanced immune responses. Despite remarkable progress, challenges related to formulation stability, long-term storage stability, safety and reactogenicity concerns, and durability of immune protection continue to hinder the broader application of mRNA-LNP vaccine platforms. This review provides an integrated overview of recent advances in mRNA-LNP vaccines, covering mRNA molecular engineering, LNP composition and delivery mechanisms, immune responses, clinical progress, and current developmental challenges. Furthermore, emerging strategies, including thermostable formulations, next-generation LNPs with improved targeting capability, emerging RNA platforms, and artificial intelligence-assisted optimization of RNA sequences and lipid materials, are discussed. By summarizing current achievements and future opportunities, this review highlights key principles guiding the rational design of safer, more stable, and more precise mRNA-LNP vaccine platforms and provides insights into accelerating their clinical translation.<\/jats:p>","DOI":"10.1186\/s43556-026-00600-7","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:31:10Z","timestamp":1790566270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA lipid nanoparticle vaccines: current status, challenges and future prospects"],"prefix":"10.1186","volume":"7","author":[{"given":"Zhineng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghu","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-5046","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"16","key":"600_CR1","doi-asserted-by":"publisher","first-page":"15231","DOI":"10.1021\/acsnano.2c12584","volume":"17","author":"Z Ye","year":"2023","unstructured":"Ye Z, Harmon J, Ni W, Li Y, Wich D, Xu Q. The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology. ACS Nano. 2023;17(16):15231\u201353. https:\/\/doi.org\/10.1021\/acsnano.2c12584.","journal-title":"ACS Nano"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cytogfr.2023.11.005","volume":"76","author":"TH Senevirathne","year":"2024","unstructured":"Senevirathne TH, Wekking D, Swain JWR, Solinas C, De Silva P. COVID-19: from emerging variants to vaccination. Cytokine Growth Factor Rev. 2024;76:127\u201341. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.11.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"600_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/medsci12020028","volume":"12","author":"LVS Kutikuppala","year":"2024","unstructured":"Kutikuppala LVS, Kourampi I, Kanagala RSD, Bhattacharjee P, Boppana SH. Prospects and challenges in developing mRNA vaccines for infectious diseases and oncogenic viruses. Med Sci (Basel). 2024;12(2):28. https:\/\/doi.org\/10.3390\/medsci12020028.","journal-title":"Med Sci (Basel)"},{"issue":"6","key":"600_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","volume":"23","author":"JR Androsavich","year":"2024","unstructured":"Androsavich JR. Frameworks for transformational breakthroughs in RNA-based medicines. Nat Rev Drug Discov. 2024;23(6):421\u201344. https:\/\/doi.org\/10.1038\/s41573-024-00943-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"600_CR5","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222462","volume":"306","author":"YJ Jeong","year":"2023","unstructured":"Jeong YJ, Wi YM, Park H, Lee JE, Kim SH, Lee KS. Current and emerging knowledge in COVID-19. Radiology. 2023;306(2):e222462. https:\/\/doi.org\/10.1148\/radiol.222462.","journal-title":"Radiology"},{"issue":"1","key":"600_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G Zhang","year":"2023","unstructured":"Zhang G, Tang T, Chen Y, Huang X, Liang T. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther. 2023;8(1):365. https:\/\/doi.org\/10.1038\/s41392-023-01579-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"20","key":"600_CR7","doi-asserted-by":"publisher","first-page":"19476","DOI":"10.1021\/acsnano.3c09781","volume":"17","author":"WCW Chan","year":"2023","unstructured":"Chan WCW, Artzi N, Chen C, Chen X, Ho D, Hu T, et al. Noble nanomedicine: celebrating groundbreaking mRNA vaccine innovations. ACS Nano. 2023;17(20):19476\u20137. https:\/\/doi.org\/10.1021\/acsnano.3c09781.","journal-title":"ACS Nano"},{"key":"600_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115190","volume":"206","author":"M Estap\u00e9 Senti","year":"2024","unstructured":"Estap\u00e9 Senti M, Garc\u00eda Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond. Adv Drug Deliv Rev. 2024;206:115190. https:\/\/doi.org\/10.1016\/j.addr.2024.115190.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"600_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00332-4","volume":"4","author":"M Makoni","year":"2023","unstructured":"Makoni M. mRNA vaccine against malaria effective in preclinical model. Lancet Microbe. 2023;4(12):e970. https:\/\/doi.org\/10.1016\/S2666-5247(23)00332-4.","journal-title":"Lancet Microbe"},{"issue":"10","key":"600_CR10","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1039\/D1CS00617G","volume":"51","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Tang Z, Huang X, Chen W, Zhou J, Liu H, et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem Soc Rev. 2022;51(10):3828\u201345. https:\/\/doi.org\/10.1039\/D1CS00617G.","journal-title":"Chem Soc Rev"},{"issue":"11","key":"600_CR11","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X Huang","year":"2022","unstructured":"Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med. 2022;28(11):2273\u201387. https:\/\/doi.org\/10.1038\/s41591-022-02061-1.","journal-title":"Nat Med"},{"key":"600_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110424","volume":"271","author":"M Fatima","year":"2025","unstructured":"Fatima M, Park PG, Hong KJ. Clinical advancements in mRNA vaccines against viral infections. Clin Immunol. 2025;271:110424. https:\/\/doi.org\/10.1016\/j.clim.2024.110424.","journal-title":"Clin Immunol"},{"issue":"15","key":"600_CR13","doi-asserted-by":"publisher","first-page":"2202688","DOI":"10.1002\/adhm.202202688","volume":"12","author":"W Yang","year":"2023","unstructured":"Yang W, Mixich L, Boonstra E, Cabral H. Polymer-based mRNA delivery strategies for advanced therapies. Adv Healthc Mater. 2023;12(15):2202688. https:\/\/doi.org\/10.1002\/adhm.202202688.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"600_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1038\/s41467-022-30059-3","volume":"13","author":"N Islam","year":"2022","unstructured":"Islam N, Sheils NE, Jarvis MS, Cohen K. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun. 2022;13(1):2377. https:\/\/doi.org\/10.1038\/s41467-022-30059-3.","journal-title":"Nat Commun"},{"issue":"1","key":"600_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bmm2.12116","volume":"3","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang X, Gao Y, Liu S. Principles of lipid nanoparticle design for mRNA delivery. BMEMat. 2025;3(1):e12116. https:\/\/doi.org\/10.1002\/bmm2.12116.","journal-title":"BMEMat"},{"issue":"24","key":"600_CR16","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2307079.","journal-title":"N Engl J Med"},{"issue":"1","key":"600_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12874-023-01967-9","volume":"23","author":"F Laher","year":"2023","unstructured":"Laher F, Malahleha M, Ramirez S, Brumskine W, Otwombe K, Moodie Z, et al. Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline. BMC Med Res Methodol. 2023;23(1):147. https:\/\/doi.org\/10.1186\/s12874-023-01967-9.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"600_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33. https:\/\/doi.org\/10.1186\/s12943-021-01311-z.","journal-title":"Mol Cancer"},{"key":"600_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100797","volume":"37","author":"BC Carleton","year":"2023","unstructured":"Carleton BC, Salmon DA, Ip P, Wong ICK, Lai FTT. Benefits v. risks of COVID-19 vaccination: an examination of vaccination policy impact on the occurrence of myocarditis and pericarditis. Lancet Reg Health West Pac. 2023;37:100797. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100797.","journal-title":"Lancet Reg Health West Pac"},{"issue":"4","key":"600_CR20","doi-asserted-by":"publisher","first-page":"E143","DOI":"10.1503\/cmaj.221068","volume":"195","author":"FTT Lai","year":"2023","unstructured":"Lai FTT, Yan VKC, Ye X, Ma T, Qin X, Chui CSL, et al. Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study. CMAJ. 2023;195(4):E143\u201352. https:\/\/doi.org\/10.1503\/cmaj.221068.","journal-title":"CMAJ"},{"issue":"27","key":"600_CR21","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"issue":"1","key":"600_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","volume":"30","author":"YS Wang","year":"2023","unstructured":"Wang YS, Kumari M, Chen GH, Hong MH, Yuan JPY, Tsai JL, et al. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J Biomed Sci. 2023;30(1):84. https:\/\/doi.org\/10.1186\/s12929-023-00977-5.","journal-title":"J Biomed Sci"},{"issue":"5","key":"600_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1894","volume":"15","author":"MZ Yu","year":"2023","unstructured":"Yu MZ, Wang NN, Zhu JQ, Lin YX. The clinical progress and challenges of mRNA vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15(5):e1894. https:\/\/doi.org\/10.1002\/wnan.1894.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"600_CR24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jconrel.2024.11.007","volume":"376","author":"K Wu","year":"2024","unstructured":"Wu K, Xu F, Dai Y, Jin S, Zheng A, Zhang N, et al. Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity. J Control Release. 2024;376:1288\u201399. https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.007.","journal-title":"J Control Release"},{"issue":"2","key":"600_CR25","doi-asserted-by":"publisher","first-page":"20210146","DOI":"10.1002\/EXP.20210146","volume":"4","author":"F Zhou","year":"2024","unstructured":"Zhou F, Huang L, Li S, Yang W, Chen F, Cai Z, et al. From structural design to delivery: mRNA therapeutics for cancer immunotherapy. Exploration (Beijing). 2024;4(2):20210146. https:\/\/doi.org\/10.1002\/EXP.20210146.","journal-title":"Exploration (Beijing)"},{"issue":"15","key":"600_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202308029","volume":"36","author":"J Wang","year":"2024","unstructured":"Wang J, Zhu H, Gan J, Liang G, Li L, Zhao Y. Engineered mRNA delivery systems for biomedical applications. Adv Mater. 2024;36(15):e2308029. https:\/\/doi.org\/10.1002\/adma.202308029.","journal-title":"Adv Mater"},{"issue":"10","key":"600_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41580-023-00622-x","volume":"24","author":"H Sun","year":"2023","unstructured":"Sun H, Li K, Liu C, Yi C. Regulation and functions of non-m6A mRNA modifications. Nat Rev Mol Cell Biol. 2023;24(10):714\u201331. https:\/\/doi.org\/10.1038\/s41580-023-00622-x.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"600_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41576-024-00712-2","volume":"25","author":"X Rambout","year":"2024","unstructured":"Rambout X, Maquat LE. Nuclear mRNA decay: regulatory networks that control gene expression. Nat Rev Genet. 2024;25(10):679\u201397. https:\/\/doi.org\/10.1038\/s41576-024-00712-2.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"600_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-023-01638-7","volume":"8","author":"C Wang","year":"2023","unstructured":"Wang C, Hou X, Guan Q, Zhou H, Zhou L, Liu L, et al. RNA modification in cardiovascular disease: implications for therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):412. https:\/\/doi.org\/10.1038\/s41392-023-01638-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"600_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41580-024-00748-6","volume":"25","author":"X Cao","year":"2024","unstructured":"Cao X, Zhang Y, Ding Y, Wan Y. Identification of RNA structures and their roles in RNA functions. Nat Rev Mol Cell Biol. 2024;25(10):784\u2013801. https:\/\/doi.org\/10.1038\/s41580-024-00748-6.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"600_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102485","volume":"36","author":"X Ma","year":"2025","unstructured":"Ma X, Liu S, Fan B, Jin D, Miao L, Liu L, et al. Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3\u2032 UTR via HuR anchorage. Mol Ther Nucleic Acids. 2025;36(2):102485. https:\/\/doi.org\/10.1016\/j.omtn.2025.102485.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"600_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/nano16040268","volume":"16","author":"A Nomani","year":"2026","unstructured":"Nomani A, Saraswat A, Brown H, Kuo JCT, Duong HTT, Wu J, et al. Identifying key factors affecting mRNA-lipid nanoparticles drug product formulation stability. Nanomaterials (Basel). 2026;16(4):268. https:\/\/doi.org\/10.3390\/nano16040268.","journal-title":"Nanomaterials (Basel)"},{"issue":"15","key":"600_CR33","doi-asserted-by":"publisher","first-page":"8818","DOI":"10.1093\/nar\/gkac635","volume":"50","author":"S Ray","year":"2022","unstructured":"Ray S, Dandpat SS, Chatterjee S, Walter NG. Precise tuning of bacterial translation initiation by non-equilibrium 5\u2032-UTR unfolding observed in single mRNAs. Nucleic Acids Res. 2022;50(15):8818\u201333. https:\/\/doi.org\/10.1093\/nar\/gkac635.","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"600_CR34","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1021\/acs.accounts.1c00541","volume":"54","author":"L Jia","year":"2021","unstructured":"Jia L, Qian SB. Therapeutic mRNA engineering from head to tail. Acc Chem Res. 2021;54(23):4272\u201382. https:\/\/doi.org\/10.1021\/acs.accounts.1c00541.","journal-title":"Acc Chem Res"},{"key":"600_CR35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.97682","volume":"13","author":"JY Su","year":"2025","unstructured":"Su JY, Wang YL, Hsieh YT, Chang YC, Yang CH, Kang YS, et al. Multiplexed assays of human disease-relevant mutations reveal UTR dinucleotide composition as a major determinant of RNA stability. Elife. 2025;13:RP97682. https:\/\/doi.org\/10.7554\/eLife.97682.","journal-title":"Elife"},{"issue":"4","key":"600_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s42256-024-00823-9","volume":"6","author":"Y Chu","year":"2024","unstructured":"Chu Y, Yu D, Li Y, Huang K, Shen Y, Cong L, et al. A 5\u2032 UTR language model for decoding untranslated regions of mRNA and function predictions. Nat Mach Intell. 2024;6(4):449\u201360. https:\/\/doi.org\/10.1038\/s42256-024-00823-9.","journal-title":"Nat Mach Intell"},{"issue":"9","key":"600_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/vaccines9090965","volume":"9","author":"S Jeeva","year":"2021","unstructured":"Jeeva S, Kim KH, Shin CH, Wang BZ, Kang SM. An update on mRNA-based viral vaccines. Vaccines (Basel). 2021;9(9):965. https:\/\/doi.org\/10.3390\/vaccines9090965.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"600_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01561-x","volume":"8","author":"D Niu","year":"2023","unstructured":"Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct Target Ther. 2023;8(1):341. https:\/\/doi.org\/10.1038\/s41392-023-01561-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"600_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1021\/acs.molpharmaceut.4c00863","volume":"22","author":"L Xu","year":"2025","unstructured":"Xu L, Li C, Liao R, Xiao Q, Wang X, Zhao Z, et al. From sequence to system: enhancing IVT mRNA vaccine effectiveness through cutting-edge technologies. Mol Pharm. 2025;22(1):81\u2013102. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00863.","journal-title":"Mol Pharm"},{"issue":"1","key":"600_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46240-9","volume":"15","author":"H Yang","year":"2024","unstructured":"Yang H, Li Q, Stroup EK, Wang S, Ji Z. Widespread stable noncanonical peptides identified by integrated analyses of ribosome profiling and ORF features. Nat Commun. 2024;15(1):1932. https:\/\/doi.org\/10.1038\/s41467-024-46240-9.","journal-title":"Nat Commun"},{"issue":"2","key":"600_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","volume":"23","author":"LA Passmore","year":"2022","unstructured":"Passmore LA, Coller J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2022;23(2):93\u2013106. https:\/\/doi.org\/10.1038\/s41580-021-00417-y.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"600_CR42","doi-asserted-by":"publisher","first-page":"317a","DOI":"10.1016\/j.bpj.2022.11.1778","volume":"122","author":"L Krause","year":"2023","unstructured":"Krause L, Chakraborty A, Willing F, Mhaindarkar V, Andreou AZ, Klostermeier D. Linking translation factor conformational dynamics with translation efficiencies and gene expression. Biophys J. 2023;122(3):317a. https:\/\/doi.org\/10.1016\/j.bpj.2022.11.1778.","journal-title":"Biophys J"},{"issue":"2","key":"600_CR43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","volume":"43","author":"H Chen","year":"2025","unstructured":"Chen H, Liu D, Guo J, Aditham A, Zhou Y, Tian J, et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat Biotechnol. 2025;43(2):194\u2013203. https:\/\/doi.org\/10.1038\/s41587-024-02174-7.","journal-title":"Nat Biotechnol"},{"key":"600_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtn.2022.10.003","volume":"30","author":"CY Li","year":"2022","unstructured":"Li CY, Liang Z, Hu Y, Zhang H, Setiasabda KD, Li J, et al. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol Ther Nucleic Acids. 2022;30:300\u201310. https:\/\/doi.org\/10.1016\/j.omtn.2022.10.003.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"686","key":"600_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023;15(686):eabn3464. https:\/\/doi.org\/10.1126\/scitranslmed.abn3464.","journal-title":"Sci Transl Med"},{"issue":"43","key":"600_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402936","volume":"11","author":"Y Gong","year":"2024","unstructured":"Gong Y, Yong D, Liu G, Xu J, Ding J, Jia W. A novel self-amplifying mRNA with decreased cytotoxicity and enhanced protein expression by macrodomain mutations. Adv Sci (Weinh). 2024;11(43):e2402936. https:\/\/doi.org\/10.1002\/advs.202402936.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"600_CR47","doi-asserted-by":"publisher","first-page":"965","DOI":"10.7150\/thno.102964","volume":"15","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Sun W, Xie J, Zhang Z, Luo J, Han X, et al. RNA nanotherapeutics for hepatocellular carcinoma treatment. Theranostics. 2025;15(3):965\u201392. https:\/\/doi.org\/10.7150\/thno.102964.","journal-title":"Theranostics"},{"issue":"2","key":"600_CR48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ymthe.2024.12.055","volume":"33","author":"IC Casmil","year":"2025","unstructured":"Casmil IC, Bathula NV, Huang C, Wayne CJ, Cairns ES, Friesen JJ, et al. Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen. Mol Ther. 2025;33(2):514\u201328. https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.055.","journal-title":"Mol Ther"},{"issue":"2","key":"600_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.32383\/appdr\/149834","volume":"79","author":"P Li","year":"2022","unstructured":"Li P, Hu J, Shi B. Baicalein suppresses LPS-induced inflammation by modulating nucleocytoplasmic transport of NF-\u03baB p65 in macrophages. Acta Pol Pharm. 2022;79(2):273\u201381. https:\/\/doi.org\/10.32383\/appdr\/149834.","journal-title":"Acta Pol Pharm"},{"issue":"1","key":"600_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B, et al. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025;10(1):73. https:\/\/doi.org\/10.1038\/s41392-024-02112-8.","journal-title":"Signal Transduct Target Ther"},{"issue":"7991","key":"600_CR51","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/d41586-023-03859-w","volume":"624","author":"E Dolgin","year":"2023","unstructured":"Dolgin E. Self-copying RNA vaccine wins first full approval: what\u2019s next? Nature. 2023;624(7991):236\u20137. https:\/\/doi.org\/10.1038\/d41586-023-03859-w.","journal-title":"Nature"},{"key":"600_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84\u201394. https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.043.","journal-title":"J Control Release"},{"issue":"2","key":"600_CR53","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R Chen","year":"2023","unstructured":"Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, et al. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2023;41(2):262\u201372. https:\/\/doi.org\/10.1038\/s41587-022-01393-0.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"600_CR54","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185(12):2016\u201334. https:\/\/doi.org\/10.1016\/j.cell.2022.04.021.","journal-title":"Cell"},{"key":"600_CR55","doi-asserted-by":"publisher","unstructured":"Wan J, Wang Z, Wang L, Wu L, Zhang C, Zhou M, et al. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses. mBio. 2024;15(1):e01775-23. https:\/\/doi.org\/10.1128\/mbio.01775-23.","DOI":"10.1128\/mbio.01775-23"},{"issue":"4","key":"600_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","volume":"26","author":"E O\u2019Leary","year":"2025","unstructured":"O\u2019Leary E, Jiang Y, Kristensen LS, Hansen TB, Kjems J. The therapeutic potential of circular RNAs. Nat Rev Genet. 2025;26(4):230\u201344. https:\/\/doi.org\/10.1038\/s41576-024-00806-x.","journal-title":"Nat Rev Genet"},{"key":"600_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113617","volume":"381","author":"Y Alshehry","year":"2025","unstructured":"Alshehry Y, Liu X, Zhang Y, Zhu G. Investigation of the impact of lipid nanoparticle compositions on the delivery and T cell response of circRNA vaccine. J Control Release. 2025;381:113617. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113617.","journal-title":"J Control Release"},{"key":"600_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114826","volume":"197","author":"TL Young","year":"2023","unstructured":"Young TL, Wang KC, Varley AJ, Li B. Clinical delivery of circular RNA: lessons learned from RNA drug development. Adv Drug Deliv Rev. 2023;197:114826. https:\/\/doi.org\/10.1016\/j.addr.2023.114826.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"600_CR59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/15476286.2019.1600395","volume":"16","author":"M Liu","year":"2019","unstructured":"Liu M, Wang Q, Shen J, Yang BB, Ding X. Circbank: a comprehensive database for circRNA with standard nomenclature. RNA Biol. 2019;16(7):899\u2013905. https:\/\/doi.org\/10.1080\/15476286.2019.1600395.","journal-title":"RNA Biol"},{"issue":"1","key":"600_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1179","volume":"53","author":"L Fan","year":"2025","unstructured":"Fan L, Zhou X, Li M, Gao A, Yu H, Tian H, et al. CICADA: a circRNA effort toward the ghost proteome. Nucleic Acids Res. 2025;53(1):gkae1179. https:\/\/doi.org\/10.1093\/nar\/gkae1179.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"600_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41418-022-00948-7","volume":"29","author":"S Misir","year":"2022","unstructured":"Misir S, Wu N, Yang BB. Specific expression and functions of circular RNAs. Cell Death Differ. 2022;29(3):481\u201391. https:\/\/doi.org\/10.1038\/s41418-022-00948-7.","journal-title":"Cell Death Differ"},{"issue":"4","key":"600_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1978","volume":"16","author":"S Wu","year":"2024","unstructured":"Wu S, Lin L, Shi L, Liu S. An overview of lipid constituents in lipid nanoparticle mRNA delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16(4):e1978. https:\/\/doi.org\/10.1002\/wnan.1978.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"23","key":"600_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202311574","volume":"36","author":"S Qi","year":"2024","unstructured":"Qi S, Zhang X, Yu X, Jin L, Yang K, Wang Y, et al. Supramolecular lipid nanoparticles based on host-guest recognition: a new generation delivery system of mRNA vaccines for cancer immunotherapy. Adv Mater. 2024;36(23):e2311574. https:\/\/doi.org\/10.1002\/adma.202311574.","journal-title":"Adv Mater"},{"issue":"5","key":"600_CR64","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/d41573-023-00002-2","volume":"22","author":"M Verma","year":"2023","unstructured":"Verma M, Ozer I, Xie W, Gallagher R, Teixeira A, Choy M. The landscape for lipid-nanoparticle-based genomic medicines. Nat Rev Drug Discov. 2023;22(5):349\u201350. https:\/\/doi.org\/10.1038\/d41573-023-00002-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"600_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202201695","volume":"7","author":"MR Hunter","year":"2023","unstructured":"Hunter MR, Cui L, Porebski BT, Pereira S, Sonzini S, Odunze U, et al. Understanding intracellular biology to improve mRNA delivery by lipid nanoparticles. Small Methods. 2023;7(9):e2201695. https:\/\/doi.org\/10.1002\/smtd.202201695.","journal-title":"Small Methods"},{"key":"600_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2023.101705","volume":"66","author":"M C\u00e1rdenas","year":"2023","unstructured":"C\u00e1rdenas M, Campbell RA, Yanez Arteta M, Lawrence MJ, Sebastiani F. Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery. Curr Opin Colloid Interface Sci. 2023;66:101705. https:\/\/doi.org\/10.1016\/j.cocis.2023.101705.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"4","key":"600_CR67","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1021\/jacs.2c10670","volume":"145","author":"G Tilstra","year":"2023","unstructured":"Tilstra G, Couture-Sen\u00e9cal J, Lau YMA, Manning AM, Wong DSM, Janaeska WW, et al. Iterative design of ionizable lipids for intramuscular mRNA delivery. J Am Chem Soc. 2023;145(4):2294\u2013304. https:\/\/doi.org\/10.1021\/jacs.2c10670.","journal-title":"J Am Chem Soc"},{"issue":"11","key":"600_CR68","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41551-024-01267-7","volume":"8","author":"X Han","year":"2024","unstructured":"Han X, Alameh MG, Xu Y, Palanki R, El-Mayta R, Dwivedi G, et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. Nat Biomed Eng. 2024;8(11):1412\u201324. https:\/\/doi.org\/10.1038\/s41551-024-01267-7.","journal-title":"Nat Biomed Eng"},{"key":"600_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115446","volume":"214","author":"K Mrksich","year":"2024","unstructured":"Mrksich K, Padilla MS, Mitchell MJ. Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. Adv Drug Deliv Rev. 2024;214:115446. https:\/\/doi.org\/10.1016\/j.addr.2024.115446.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"600_CR70","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov. 2024;23(9):709\u201322. https:\/\/doi.org\/10.1038\/s41573-024-00977-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"44","key":"600_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202407398","volume":"63","author":"M Cheng","year":"2024","unstructured":"Cheng M, Yu X, Qi S, Yang K, Lu M, Cao F, et al. Development of organ targeting lipid nanoparticles with low immunogenicity and their application in the treatment of pulmonary fibrosis. Angew Chem Int Ed Engl. 2024;63(44):e202407398. https:\/\/doi.org\/10.1002\/anie.202407398.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"600_CR72","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"key":"600_CR73","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jconrel.2024.07.059","volume":"373","author":"T Oguma","year":"2024","unstructured":"Oguma T, Kanazawa T, Kaneko YK, Sato R, Serizawa M, Ooka A, et al. Effects of phospholipid type and particle size on lipid nanoparticle distribution in vivo and in pancreatic islets. J Control Release. 2024;373:917\u201328. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.059.","journal-title":"J Control Release"},{"issue":"20","key":"600_CR74","doi-asserted-by":"publisher","first-page":"8304","DOI":"10.1021\/acs.nanolett.2c03234","volume":"22","author":"S Luozhong","year":"2022","unstructured":"Luozhong S, Yuan Z, Sarmiento T, Chen Y, Gu W, McCurdy C, et al. Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs. Nano Lett. 2022;22(20):8304\u201311. https:\/\/doi.org\/10.1021\/acs.nanolett.2c03234.","journal-title":"Nano Lett"},{"issue":"42","key":"600_CR75","doi-asserted-by":"publisher","first-page":"28480","DOI":"10.1021\/acsnano.4c06369","volume":"18","author":"PI Back","year":"2024","unstructured":"Back PI, Yu M, Modaresahmadi S, Hajimirzaei S, Zhang Q, Islam MR, et al. Immune implications of cholesterol-containing lipid nanoparticles. ACS Nano. 2024;18(42):28480\u2013501. https:\/\/doi.org\/10.1021\/acsnano.4c06369.","journal-title":"ACS Nano"},{"issue":"12","key":"600_CR76","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"11","key":"600_CR77","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","volume":"3","author":"SS Nogueira","year":"2020","unstructured":"Nogueira SS, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer MA, et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl Nano Mater. 2020;3(11):10634\u201345. https:\/\/doi.org\/10.1021\/acsanm.0c01834.","journal-title":"ACS Appl Nano Mater"},{"key":"600_CR78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bioactmat.2024.03.017","volume":"37","author":"DD Kang","year":"2024","unstructured":"Kang DD, Hou X, Wang L, Xue Y, Li H, Zhong Y, et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact Mater. 2024;37:86\u201393. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.03.017.","journal-title":"Bioact Mater"},{"key":"600_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114266","volume":"198","author":"M Ongun","year":"2024","unstructured":"Ongun M, Lokras AG, Baghel S, Shi Z, Schmidt ST, Franzyk H, et al. Lipid nanoparticles for local delivery of mRNA to the respiratory tract: effect of PEG-lipid content and administration route. Eur J Pharm Biopharm. 2024;198:114266. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114266.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"600_CR80","doi-asserted-by":"publisher","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","volume":"16","author":"J Kim","year":"2022","unstructured":"Kim J, Jozic A, Lin Y, Eygeris Y, Bloom E, Tan X, et al. Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation. ACS Nano. 2022;16(9):14792\u2013806. https:\/\/doi.org\/10.1021\/acsnano.2c05647.","journal-title":"ACS Nano"},{"issue":"8","key":"600_CR81","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/pharmaceutics17080950","volume":"17","author":"W Liu","year":"2025","unstructured":"Liu W, Zhang M, Lv H, Yang C. Formulation-driven optimization of PEG-lipid content in lipid nanoparticles for enhanced mRNA delivery in vitro and in vivo. Pharmaceutics. 2025;17(8):950. https:\/\/doi.org\/10.3390\/pharmaceutics17080950.","journal-title":"Pharmaceutics"},{"issue":"11","key":"600_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111423","volume":"16","author":"M Li","year":"2024","unstructured":"Li M, Yi J, Lu Y, Liu T, Xing H, Wang X, et al. Modified PEG-lipids enhance the nasal mucosal immune capacity of lipid nanoparticle mRNA vaccines. Pharmaceutics. 2024;16(11):1423. https:\/\/doi.org\/10.3390\/pharmaceutics16111423.","journal-title":"Pharmaceutics"},{"issue":"12","key":"600_CR83","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh MG, Tomb\u00e1cz I, Bettini E, Lederer K, Ndeupen S, Sittplangkoon C, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877-2892.e7. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.001.","journal-title":"Immunity"},{"issue":"1","key":"600_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"S Kim","year":"2024","unstructured":"Kim S, Jeon JH, Kim M, Lee Y, Hwang YH, Park M, et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site. Nat Commun. 2024;15(1):7226. https:\/\/doi.org\/10.1038\/s41467-024-51411-9.","journal-title":"Nat Commun"},{"issue":"1","key":"600_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00684-0","volume":"8","author":"HJ Park","year":"2023","unstructured":"Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, et al. Analyzing immune responses to varied mRNA and protein vaccine sequences. NPJ Vaccines. 2023;8(1):84. https:\/\/doi.org\/10.1038\/s41541-023-00684-0.","journal-title":"NPJ Vaccines"},{"issue":"11","key":"600_CR86","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","volume":"8","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary N, Kasiewicz LN, Newby AN, Arral ML, Yerneni SS, Melamed JR, et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat Biomed Eng. 2024;8(11):1483\u201398. https:\/\/doi.org\/10.1038\/s41551-024-01256-w.","journal-title":"Nat Biomed Eng"},{"issue":"10","key":"600_CR87","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55(10):2085\u201396. https:\/\/doi.org\/10.1038\/s12276-023-01086-x.","journal-title":"Exp Mol Med"},{"issue":"12","key":"600_CR88","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/pharmaceutics16121521","volume":"16","author":"L Catenacci","year":"2024","unstructured":"Catenacci L, Rossi R, Sechi F, Buonocore D, Sorrenti M, Perteghella S, et al. Effect of lipid nanoparticle physico-chemical properties and composition on their interaction with the immune system. Pharmaceutics. 2024;16(12):1521. https:\/\/doi.org\/10.3390\/pharmaceutics16121521.","journal-title":"Pharmaceutics"},{"issue":"6","key":"600_CR89","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840\u201354. https:\/\/doi.org\/10.1038\/s41587-022-01294-2.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"600_CR90","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1208\/s12249-021-02058-y","volume":"22","author":"N Khehra","year":"2021","unstructured":"Khehra N, Padda I, Jaferi U, Atwal H, Narain S, Parmar MS. Tozinameran (BNT162b2) vaccine: the journey from preclinical research to clinical trials and authorization. AAPS PharmSciTech. 2021;22(5):172. https:\/\/doi.org\/10.1208\/s12249-021-02058-y.","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"600_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11111532","volume":"11","author":"P Ratajczak","year":"2023","unstructured":"Ratajczak P, Banach Z, Kopciuch D, Paczkowska A, Zaprutko T, Krawczyk J, et al. Tozinameran (Pfizer, BioNTech) and elasomeran (Moderna) efficacy in COVID-19-a systematic review of randomised controlled trial studies. Healthcare (Basel). 2023;11(11):1532. https:\/\/doi.org\/10.3390\/healthcare11111532.","journal-title":"Healthcare (Basel)"},{"issue":"3","key":"600_CR92","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","volume":"3","author":"GL Chen","year":"2022","unstructured":"Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022;3(3):e193\u2013202. https:\/\/doi.org\/10.1016\/S2666-5247(21)00280-9.","journal-title":"Lancet Microbe"},{"key":"600_CR93","doi-asserted-by":"publisher","first-page":"1468775","DOI":"10.3389\/fcimb.2024.1468775","volume":"14","author":"H Huo","year":"2024","unstructured":"Huo H, Wang J, Li C, Xiao S, Wang H, Ge J, et al. Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs. Front Cell Infect Microbiol. 2024;14:1468775. https:\/\/doi.org\/10.3389\/fcimb.2024.1468775.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"600_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29417","volume":"96","author":"X Yang","year":"2024","unstructured":"Yang X, Wang Y, Liang Z, Cui T, Chen D, Li G, et al. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations. J Med Virol. 2024;96(1):e29417. https:\/\/doi.org\/10.1002\/jmv.29417.","journal-title":"J Med Virol"},{"issue":"5","key":"600_CR95","doi-asserted-by":"publisher","first-page":"e996","DOI":"10.1093\/infdis\/jiae316","volume":"230","author":"J Goswami","year":"2024","unstructured":"Goswami J, Baqui AH, Doreski PA, Perez Marc G, Jimenez G, Ahmed S, et al. Humoral immunogenicity of mRNA-1345 RSV vaccine in older adults. J Infect Dis. 2024;230(5):e996\u20131006. https:\/\/doi.org\/10.1093\/infdis\/jiae316.","journal-title":"J Infect Dis"},{"issue":"4","key":"600_CR96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2. Lancet Infect Dis. 2024;24(4):341\u20133. https:\/\/doi.org\/10.1016\/S1473-3099(24)00060-4.","journal-title":"Lancet Infect Dis"},{"issue":"35","key":"600_CR97","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2174\/1381612828666220701160116","volume":"28","author":"R Yogesh","year":"2022","unstructured":"Yogesh R, Srivastava N, Abbas Bukhari SN. COVID-19 challenge: a quest for effective vaccine strategies against circulating and emerging SARS-CoV-2 variants. Curr Pharm Des. 2022;28(35):2901\u201313. https:\/\/doi.org\/10.2174\/1381612828666220701160116.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"600_CR98","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ymthe.2024.02.011","volume":"32","author":"N Wu","year":"2024","unstructured":"Wu N, Zhang J, Shen Y, Zhang X, Zhou J, Wu Y, et al. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections. Mol Ther. 2024;32(4):1033\u201347. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.011.","journal-title":"Mol Ther"},{"issue":"8","key":"600_CR99","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.jamda.2021.06.006","volume":"22","author":"DA Nace","year":"2021","unstructured":"Nace DA, Kip KE, Mellors JW, Peck Palmer OM, Shurin MR, Mulvey K, et al. Antibody responses after mRNA-based COVID-19 vaccination in residential older adults: implications for reopening. J Am Med Dir Assoc. 2021;22(8):1593\u20138. https:\/\/doi.org\/10.1016\/j.jamda.2021.06.006.","journal-title":"J Am Med Dir Assoc"},{"issue":"7","key":"600_CR100","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","volume":"28","author":"IP Trougakos","year":"2022","unstructured":"Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28(7):542\u201354. https:\/\/doi.org\/10.1016\/j.molmed.2022.04.007.","journal-title":"Trends Mol Med"},{"issue":"3","key":"600_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106447","volume":"90","author":"N Mazarakis","year":"2025","unstructured":"Mazarakis N, Toh ZQ, Neal E, Bright K, Luu S, Quah L, et al. The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose. J Infect. 2025;90(3):106447. https:\/\/doi.org\/10.1016\/j.jinf.2025.106447.","journal-title":"J Infect"},{"key":"600_CR102","doi-asserted-by":"publisher","first-page":"1051576","DOI":"10.3389\/fimmu.2022.1051576","volume":"13","author":"K Xu","year":"2023","unstructured":"Xu K, Lei W, Kang B, Yang H, Wang Y, Lu Y, et al. A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Front Immunol. 2023;13:1051576. https:\/\/doi.org\/10.3389\/fimmu.2022.1051576.","journal-title":"Front Immunol"},{"issue":"1","key":"600_CR103","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/14760584.2024.2354251","volume":"23","author":"C Hu","year":"2024","unstructured":"Hu C, Bai Y, Liu J, Wang Y, He Q, Zhang X, et al. Research progress on the quality control of mRNA vaccines. Expert Rev Vaccines. 2024;23(1):570\u201383. https:\/\/doi.org\/10.1080\/14760584.2024.2354251.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"600_CR104","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/d41591-023-00017-7","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho T. mRNA vaccine effective against RSV respiratory disease. Nat Med. 2023;29(4):755\u20136. https:\/\/doi.org\/10.1038\/d41591-023-00017-7.","journal-title":"Nat Med"},{"issue":"11","key":"600_CR105","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817\u201338. https:\/\/doi.org\/10.1038\/s41573-021-00283-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"600_CR106","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1021\/acs.molpharmaceut.4c00276","volume":"21","author":"J Li","year":"2024","unstructured":"Li J, Zhang Y, Yang YG, Sun T. Advancing mRNA therapeutics: the role and future of nanoparticle delivery systems. Mol Pharm. 2024;21(8):3743\u201363. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00276.","journal-title":"Mol Pharm"},{"issue":"1","key":"600_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01432-5","volume":"8","author":"Y Sang","year":"2023","unstructured":"Sang Y, Zhang Z, Liu F, Lu H, Yu C, Sun H, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Signal Transduct Target Ther. 2023;8(1):172. https:\/\/doi.org\/10.1038\/s41392-023-01432-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"600_CR108","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10930-023-10150-4","volume":"42","author":"SV Ramprasadh","year":"2023","unstructured":"Ramprasadh SV, Rajakumar S, Srinivasan S, Susha D, Sharma S, Chourasiya R. Computer-aided multi-epitope based vaccine design against monkeypox virus surface protein A30L: an immunoinformatics approach. Protein J. 2023;42(6):645\u201363. https:\/\/doi.org\/10.1007\/s10930-023-10150-4.","journal-title":"Protein J"},{"issue":"1","key":"600_CR109","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","volume":"8","author":"B Bollman","year":"2023","unstructured":"Bollman B, Nunna N, Bahl K, Hsiao CJ, Bennett H, Butler S, et al. An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection. NPJ Vaccines. 2023;8(1):58. https:\/\/doi.org\/10.1038\/s41541-023-00656-4.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"600_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgeb.2025.100469","volume":"23","author":"A Hussain","year":"2025","unstructured":"Hussain A, Fareed A. Personalized medicine in pancreatic cancer: harnessing the potential of mRNA vaccines. J Genet Eng Biotechnol. 2025;23(1):100469. https:\/\/doi.org\/10.1016\/j.jgeb.2025.100469.","journal-title":"J Genet Eng Biotechnol"},{"issue":"7644","key":"600_CR111","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248\u201351. https:\/\/doi.org\/10.1038\/nature21428.","journal-title":"Nature"},{"issue":"6622","key":"600_CR112","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.adf0900","volume":"378","author":"AA Kelvin","year":"2022","unstructured":"Kelvin AA, Falzarano D. The influenza universe in an mRNA vaccine. Science. 2022;378(6622):827\u20138. https:\/\/doi.org\/10.1126\/science.adf0900.","journal-title":"Science"},{"issue":"1","key":"600_CR113","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","volume":"13","author":"N Pardi","year":"2022","unstructured":"Pardi N, Carre\u00f1o JM, O\u2019Dell G, Tan J, Bajusz C, Muramatsu H, et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat Commun. 2022;13(1):4677. https:\/\/doi.org\/10.1038\/s41467-022-32149-8.","journal-title":"Nat Commun"},{"issue":"1","key":"600_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00478-w","volume":"7","author":"Q Ye","year":"2022","unstructured":"Ye Q, Wu M, Zhou C, Lu X, Huang B, Zhang N, et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines. 2022;7(1):84. https:\/\/doi.org\/10.1038\/s41541-022-00478-w.","journal-title":"NPJ Vaccines"},{"issue":"11","key":"600_CR115","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.4049\/jimmunol.2001287","volume":"206","author":"AM Sandor","year":"2021","unstructured":"Sandor AM, Sturdivant MS, Ting JPY. Influenza virus and SARS-CoV-2 vaccines. J Immunol. 2021;206(11):2509\u201320. https:\/\/doi.org\/10.4049\/jimmunol.2001287.","journal-title":"J Immunol"},{"issue":"5","key":"600_CR116","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ymthe.2025.02.016","volume":"33","author":"JS Tregoning","year":"2025","unstructured":"Tregoning JS, Sanders NN. The past, present, and future of RNA vaccines. Mol Ther. 2025;33(5):1876\u20138. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.016.","journal-title":"Mol Ther"},{"issue":"50","key":"600_CR117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217533119","volume":"119","author":"S Pecetta","year":"2022","unstructured":"Pecetta S, Rappuoli R. mRNA, the beginning of a new influenza vaccine game. Proc Natl Acad Sci U S A. 2022;119(50):e2217533119. https:\/\/doi.org\/10.1073\/pnas.2217533119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"600_CR118","doi-asserted-by":"publisher","first-page":"1008684","DOI":"10.3389\/fmicb.2022.1008684","volume":"13","author":"Y Tian","year":"2022","unstructured":"Tian Y, Deng Z, Yang P. mRNA vaccines: A novel weapon to control infectious diseases. Front Microbiol. 2022;13:1008684. https:\/\/doi.org\/10.3389\/fmicb.2022.1008684.","journal-title":"Front Microbiol"},{"issue":"1","key":"600_CR119","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi Y, Shi M, Wang Y, You J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct Target Ther. 2024;9(1):322. https:\/\/doi.org\/10.1038\/s41392-024-02002-z.","journal-title":"Signal Transduct Target Ther"},{"key":"600_CR120","doi-asserted-by":"publisher","first-page":"1099991","DOI":"10.3389\/fimmu.2022.1099991","volume":"13","author":"S Bai","year":"2023","unstructured":"Bai S, Yang T, Zhu C, Feng M, Zhang L, Zhang Z, et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. Front Immunol. 2023;13:1099991. https:\/\/doi.org\/10.3389\/fimmu.2022.1099991.","journal-title":"Front Immunol"},{"issue":"1","key":"600_CR121","doi-asserted-by":"publisher","first-page":"2396886","DOI":"10.1080\/22221751.2024.2396886","volume":"13","author":"Q Ge","year":"2024","unstructured":"Ge Q, Chen P, Cheng Y, Xiao Y. The long road for vaccine development with difficulties and hopes. Emerg Microbes Infect. 2024;13(1):2396886. https:\/\/doi.org\/10.1080\/22221751.2024.2396886.","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"600_CR122","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2352-3018(23)00264-3","volume":"11","author":"JP Nkolola","year":"2024","unstructured":"Nkolola JP, Barouch DH. Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet HIV. 2024;11(2):e117\u201324. https:\/\/doi.org\/10.1016\/S2352-3018(23)00264-3.","journal-title":"Lancet HIV"},{"key":"600_CR123","doi-asserted-by":"publisher","unstructured":"Nitika, Wei J, Hui AM. The development of mRNA vaccines for infectious diseases: recent updates. Infect Drug Resist. 2021;14:5271\u20135285. https:\/\/doi.org\/10.2147\/IDR.S341694.","DOI":"10.2147\/IDR.S341694"},{"issue":"7","key":"600_CR124","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024;21(7):489\u2013500. https:\/\/doi.org\/10.1038\/s41571-024-00902-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"600_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, et al. mRNA vaccine in cancer therapy: current advance and future outlook. Clin Transl Med. 2023;13(8):e1384. https:\/\/doi.org\/10.1002\/ctm2.1384.","journal-title":"Clin Transl Med"},{"key":"600_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121020","volume":"607","author":"Q Shuai","year":"2021","unstructured":"Shuai Q, Zhu F, Zhao M, Yan Y. mRNA delivery via non-viral carriers for biomedical applications. Int J Pharm. 2021;607:121020. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121020.","journal-title":"Int J Pharm"},{"issue":"10432","key":"600_CR127","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403(10432):1192\u2013204. https:\/\/doi.org\/10.1016\/S0140-6736(23)02444-3.","journal-title":"Lancet"},{"key":"600_CR128","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcis.2023.12.165","volume":"660","author":"J Gilbert","year":"2024","unstructured":"Gilbert J, Sebastiani F, Yanez Arteta M, Terry A, Fornell A, Russell R, et al. Evolution of the structure of lipid nanoparticles for nucleic acid delivery: from in situ studies of formulation to colloidal stability. J Colloid Interface Sci. 2024;660:66\u201376. https:\/\/doi.org\/10.1016\/j.jcis.2023.12.165.","journal-title":"J Colloid Interface Sci"},{"key":"600_CR129","doi-asserted-by":"publisher","unstructured":"Hammer H, Kamm CP, Salmen A, Hoepner R. Comparable efficacy of SARS-CoV-2 mRNA vaccines (BNT162b2 and mRNA-1273) in Fingolimod-treated patients with multiple sclerosis. Biomed J Sci Tech Res. 2023;50(1):41203\u201341205. https:\/\/doi.org\/10.26717\/BJSTR.2023.50.007885.","DOI":"10.26717\/BJSTR.2023.50.007885"},{"issue":"3","key":"600_CR130","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","volume":"110","author":"DJA Crommelin","year":"2021","unstructured":"Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110(3):997\u20131001. https:\/\/doi.org\/10.1016\/j.xphs.2020.12.006.","journal-title":"J Pharm Sci"},{"key":"600_CR131","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jconrel.2024.07.052","volume":"373","author":"Y Fan","year":"2024","unstructured":"Fan Y, Rigas D, Kim LJ, Chang FP, Zang N, McKee K, et al. Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings. J Control Release. 2024;373:727\u201337. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.052.","journal-title":"J Control Release"},{"issue":"11","key":"600_CR132","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3390\/vaccines10111971","volume":"10","author":"SA Meo","year":"2022","unstructured":"Meo SA, Al-Masri AA, Klonoff DC, Alshahrani AN, Al-Khlaiwi T. Comparison of biological, pharmacological characteristics, indications, contraindications and adverse effects of JYNNEOS and ACAM2000 monkeypox vaccines. Vaccines (Basel). 2022;10(11):1971. https:\/\/doi.org\/10.3390\/vaccines10111971.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"600_CR133","doi-asserted-by":"publisher","first-page":"2002083","DOI":"10.1080\/21645515.2021.2002083","volume":"18","author":"R Patel","year":"2022","unstructured":"Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022;18(1):2002083. https:\/\/doi.org\/10.1080\/21645515.2021.2002083.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"600_CR134","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.medj.2021.12.002","volume":"3","author":"A Puranik","year":"2022","unstructured":"Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O\u2019Horo JC, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med. 2022;3(1):28-41.e8. https:\/\/doi.org\/10.1016\/j.medj.2021.12.002.","journal-title":"Med"},{"issue":"8","key":"600_CR135","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/biom14081036","volume":"14","author":"N Parvin","year":"2024","unstructured":"Parvin N, Joo SW, Mandal TK. Enhancing vaccine efficacy and stability: a review of the utilization of nanoparticles in mRNA vaccines. Biomolecules. 2024;14(8):1036. https:\/\/doi.org\/10.3390\/biom14081036.","journal-title":"Biomolecules"},{"key":"600_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124514","volume":"662","author":"T Wang","year":"2024","unstructured":"Wang T, Yu T, Li W, Liu Q, Sung TC, Higuchi A. Design and lyophilization of mRNA-encapsulating lipid nanoparticles. Int J Pharm. 2024;662:124514. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124514.","journal-title":"Int J Pharm"},{"issue":"3","key":"600_CR137","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/v15030668","volume":"15","author":"F Cheng","year":"2023","unstructured":"Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, et al. Research advances on the stability of mRNA vaccines. Viruses. 2023;15(3):668. https:\/\/doi.org\/10.3390\/v15030668.","journal-title":"Viruses"},{"issue":"12","key":"600_CR138","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41573-024-01041-z","volume":"23","author":"A Gupta","year":"2024","unstructured":"Gupta A, Rudra A, Reed K, Langer R, Anderson DG. Advanced technologies for the development of infectious disease vaccines. Nat Rev Drug Discov. 2024;23(12):914\u201338. https:\/\/doi.org\/10.1038\/s41573-024-01041-z.","journal-title":"Nat Rev Drug Discov"},{"key":"600_CR139","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-chembioeng-100724-084241","volume":"17","author":"B Gao","year":"2026","unstructured":"Gao B, He S, Sun Q. Strategies to improve the stability and translation of therapeutic mRNAs. Annu Rev Chem Biomol Eng. 2026;17:309\u201324. https:\/\/doi.org\/10.1146\/annurev-chembioeng-100724-084241.","journal-title":"Annu Rev Chem Biomol Eng"},{"issue":"2","key":"600_CR140","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/vaccines9020081","volume":"9","author":"I Knezevic","year":"2021","unstructured":"Knezevic I, Liu MA, Peden K, Zhou T, Kang HN. Development of mRNA vaccines: scientific and regulatory issues. Vaccines (Basel). 2021;9(2):81. https:\/\/doi.org\/10.3390\/vaccines9020081.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"600_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1992","volume":"16","author":"X Jiao","year":"2024","unstructured":"Jiao X, He X, Qin S, Yin X, Song T, Duan X, et al. Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16(5):e1992. https:\/\/doi.org\/10.1002\/wnan.1992.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"1","key":"600_CR142","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar M, Pepin CS, Moore MJ. Tailor made: the art of therapeutic mRNA design. Nat Rev Drug Discov. 2024;23(1):67\u201383. https:\/\/doi.org\/10.1038\/s41573-023-00827-x.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"600_CR143","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/vaccines12080873","volume":"12","author":"Z Wu","year":"2024","unstructured":"Wu Z, Sun W, Qi H. Recent advancements in mRNA vaccines: from target selection to delivery systems. Vaccines (Basel). 2024;12(8):873. https:\/\/doi.org\/10.3390\/vaccines12080873.","journal-title":"Vaccines (Basel)"},{"issue":"13","key":"600_CR144","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.3390\/ijms241310514","volume":"24","author":"H Banoun","year":"2023","unstructured":"Banoun H. mRNA: vaccine or gene therapy? The safety regulatory issues. Int J Mol Sci. 2023;24(13):10514. https:\/\/doi.org\/10.3390\/ijms241310514.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"600_CR145","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/0115748855267031240102070325","volume":"20","author":"S Tyagi","year":"2025","unstructured":"Tyagi S, Shukla VK, Arora S. CMC and QMS regulatory requirements and challenges for mRNA-based vaccines. Curr Drug Ther. 2025;20(2):149\u201360. https:\/\/doi.org\/10.2174\/0115748855267031240102070325.","journal-title":"Curr Drug Ther"},{"issue":"1","key":"600_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IECV2023-16530","volume":"26","author":"R Bouderhem","year":"2024","unstructured":"Bouderhem R. Challenges faced by states and the WHO in efficiently regulating the use of mRNA vaccines. Med Sci Forum. 2024;26(1):1. https:\/\/doi.org\/10.3390\/IECV2023-16530.","journal-title":"Med Sci Forum"},{"key":"600_CR147","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/82_2020_220","volume":"440","author":"R Naik","year":"2022","unstructured":"Naik R, Peden K. Regulatory considerations on the development of mRNA vaccines. Curr Top Microbiol Immunol. 2022;440:187\u2013205. https:\/\/doi.org\/10.1007\/82_2020_220.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"600_CR148","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41541-023-00732-9","volume":"8","author":"M Li","year":"2023","unstructured":"Li M, Jia L, Xie Y, Ma W, Yan Z, Liu F, et al. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. NPJ Vaccines. 2023;8(1):153. https:\/\/doi.org\/10.1038\/s41541-023-00732-9.","journal-title":"NPJ Vaccines"},{"issue":"3","key":"600_CR149","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700. https:\/\/doi.org\/10.3390\/ijms24032700.","journal-title":"Int J Mol Sci"},{"key":"600_CR150","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-biochem-052621-091808","volume":"92","author":"Q Wu","year":"2023","unstructured":"Wu Q, Bazzini AA. Translation and mRNA stability control. Annu Rev Biochem. 2023;92:227\u201345. https:\/\/doi.org\/10.1146\/annurev-biochem-052621-091808.","journal-title":"Annu Rev Biochem"},{"issue":"24","key":"600_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29245978","volume":"29","author":"IV Kornienko","year":"2024","unstructured":"Kornienko IV, Aramova OY, Tishchenko AA, Rudoy DV, Chikindas ML. RNA stability: a review of the role of structural features and environmental conditions. Molecules. 2024;29(24):5978. https:\/\/doi.org\/10.3390\/molecules29245978.","journal-title":"Molecules"},{"issue":"1","key":"600_CR152","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek K, Byeon GW, Kladwang W, Wayment-Steele HK, Kerr CH, Xu AF, et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat Commun. 2022;13(1):1536. https:\/\/doi.org\/10.1038\/s41467-022-28776-w.","journal-title":"Nat Commun"},{"issue":"1","key":"600_CR153","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1039\/D3CS00194F","volume":"53","author":"H Zhang","year":"2024","unstructured":"Zhang H, Vandesompele J, Braeckmans K, De Smedt SC, Remaut K. Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity. Chem Soc Rev. 2024;53(1):317\u201360. https:\/\/doi.org\/10.1039\/D3CS00194F.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"600_CR154","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","volume":"113","author":"U Chheda","year":"2024","unstructured":"Chheda U, Pradeepan S, Esposito E, Strezsak S, Fernandez-Delgado O, Kranz J. Factors affecting stability of RNA - temperature, length, concentration, pH, and buffering species. J Pharm Sci. 2024;113(2):377\u201385. https:\/\/doi.org\/10.1016\/j.xphs.2023.11.023.","journal-title":"J Pharm Sci"},{"key":"600_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125114","volume":"670","author":"R Wang","year":"2025","unstructured":"Wang R, Zhang Y, Zhong H, Zang J, Wang W, Cheng H, et al. Understanding the self-assembly and molecular structure of mRNA lipid nanoparticles at real size: Insights from the ultra-large-scale simulation. Int J Pharm. 2025;670:125114. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.125114.","journal-title":"Int J Pharm"},{"issue":"1","key":"600_CR156","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2\u201312. https:\/\/doi.org\/10.1021\/acs.accounts.1c00544.","journal-title":"Acc Chem Res"},{"issue":"2","key":"600_CR157","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/17425247.2023.2162876","volume":"20","author":"A De","year":"2023","unstructured":"De A, Ko YT. Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out. Expert Opin Drug Deliv. 2023;20(2):175\u201387. https:\/\/doi.org\/10.1080\/17425247.2023.2162876.","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"600_CR158","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1021\/acs.langmuir.2c02657","volume":"39","author":"ZJ Jakubek","year":"2023","unstructured":"Jakubek ZJ, Chen S, Zaifman J, Tam YYC, Zou S. Lipid nanoparticle and liposome reference materials: assessment of size homogeneity and long-term -70 \u00b0C and 4 \u00b0C storage stability. Langmuir. 2023;39(7):2509\u201319. https:\/\/doi.org\/10.1021\/acs.langmuir.2c02657.","journal-title":"Langmuir"},{"issue":"10","key":"600_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241006","volume":"15","author":"RC Ryals","year":"2020","unstructured":"Ryals RC, Patel S, Acosta C, McKinney M, Pennesi ME, Sahay G. The effects of PEGylation on LNP based mRNA delivery to the eye. PLoS ONE. 2020;15(10):e0241006. https:\/\/doi.org\/10.1371\/journal.pone.0241006.","journal-title":"PLoS ONE"},{"key":"600_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125297","volume":"672","author":"L Hourdel","year":"2025","unstructured":"Hourdel L, Lebaz N, Peral F, Ripoll M, Brian\u00e7on S, Bensaid F, et al. Overview on LNP-mRNA encapsulation unit operation: mixing technologies, scalability, and influence of formulation & process parameters on physico-chemical characteristics. Int J Pharm. 2025;672:125297. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125297.","journal-title":"Int J Pharm"},{"issue":"3","key":"600_CR161","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1021\/acs.molpharmaceut.5c01407","volume":"23","author":"CY Du","year":"2026","unstructured":"Du CY, Gao H, Jia F, Ding ZL, Fang WJ. Impact of silicone oil and storage conditions on the physicochemical and functional stability of mRNA-LNPs: the critical role of mRNA structure. Mol Pharm. 2026;23(3):1667\u201380. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01407.","journal-title":"Mol Pharm"},{"key":"600_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416. https:\/\/doi.org\/10.1016\/j.addr.2022.114416.","journal-title":"Adv Drug Deliv Rev"},{"key":"600_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.113807","volume":"236","author":"HC Huang","year":"2024","unstructured":"Huang HC, Lin CJ, Sheng YJ, Tsao HK. Instability of membranes containing ionizable cationic lipids: effects of the repulsive range of headgroups and tail structures. Colloids Surf B Biointerfaces. 2024;236:113807. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113807.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"600_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124942","volume":"668","author":"B Binici","year":"2025","unstructured":"Binici B, Borah A, Watts JA, McLoughlin D, Perrie Y. The influence of citrate buffer molarity on mRNA-LNPs: exploring factors beyond general critical quality attributes. Int J Pharm. 2025;668:124942. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124942.","journal-title":"Int J Pharm"},{"issue":"7","key":"600_CR165","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.013.","journal-title":"Mol Ther"},{"issue":"8","key":"600_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/anbr.202300006","volume":"3","author":"X Tang","year":"2023","unstructured":"Tang X, Zhang Y, Han X. Ionizable lipid nanoparticles for mRNA delivery. Adv NanoBiomed Res. 2023;3(8):2300006. https:\/\/doi.org\/10.1002\/anbr.202300006.","journal-title":"Adv NanoBiomed Res"},{"issue":"45","key":"600_CR167","doi-asserted-by":"publisher","first-page":"21733","DOI":"10.1039\/C9NR09347H","volume":"11","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni JA, Witzigmann D, Leung J, Tam YYC, Cullis PR. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale. 2019;11(45):21733\u20139. https:\/\/doi.org\/10.1039\/C9NR09347H.","journal-title":"Nanoscale"},{"issue":"12","key":"600_CR168","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1016\/j.bbamem.2012.08.007","volume":"1818","author":"C Roos","year":"2012","unstructured":"Roos C, Zocher M, M\u00fcller D, M\u00fcnch D, Schneider T, Sahl HG, et al. Characterization of co-translationally formed nanodisc complexes with small multidrug transporters, proteorhodopsin and with the E. coli MraY translocase. Biochim Biophys Acta. 2012;1818(12):3098\u2013106. https:\/\/doi.org\/10.1016\/j.bbamem.2012.08.007.","journal-title":"Biochim Biophys Acta"},{"issue":"33","key":"600_CR169","doi-asserted-by":"publisher","first-page":"19943","DOI":"10.1073\/pnas.2002200117","volume":"117","author":"FA Heberle","year":"2020","unstructured":"Heberle FA, Doktorova M, Scott HL, Skinkle AD, Waxham MN, Levental I. Direct label-free imaging of nanodomains in biomimetic and biological membranes by cryogenic electron microscopy. Proc Natl Acad Sci U S A. 2020;117(33):19943\u201352. https:\/\/doi.org\/10.1073\/pnas.2002200117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"600_CR170","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"AA D'Souza","year":"2016","unstructured":"D\u2019Souza AA, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 2016;13(9):1257\u201375. https:\/\/doi.org\/10.1080\/17425247.2016.1182485.","journal-title":"Expert Opin Drug Deliv"},{"key":"600_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.polymdegradstab.2020.109388","volume":"183","author":"ME Payne","year":"2021","unstructured":"Payne ME, Kareem OO, Williams-Pavlantos K, Wesdemiotis C, Grayson SM. Mass spectrometry investigation into the oxidative degradation of poly(ethylene glycol). Polym Degrad Stab. 2021;183:109388. https:\/\/doi.org\/10.1016\/j.polymdegradstab.2020.109388.","journal-title":"Polym Degrad Stab"},{"key":"600_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114309","volume":"185","author":"W Wang","year":"2022","unstructured":"Wang W, Huang Z, Huang Y, Zhang X, Huang J, Cui Y, et al. Pulmonary delivery nanomedicines towards circumventing physiological barriers: strategies and characterization approaches. Adv Drug Deliv Rev. 2022;185:114309. https:\/\/doi.org\/10.1016\/j.addr.2022.114309.","journal-title":"Adv Drug Deliv Rev"},{"key":"600_CR173","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","volume":"30","author":"N Chander","year":"2023","unstructured":"Chander N, Basha G, Cheng MHY, Witzigmann D, Cullis PR. Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues. Mol Ther Methods Clin Dev. 2023;30:235\u201345. https:\/\/doi.org\/10.1016\/j.omtm.2023.06.005.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"600_CR174","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40779-023-00445-z","volume":"10","author":"YQ Zhang","year":"2023","unstructured":"Zhang YQ, Guo RR, Chen YH, Li TC, Du WZ, Xiang RW, et al. Ionizable drug delivery systems for efficient and selective gene therapy. Mil Med Res. 2023;10(1):9. https:\/\/doi.org\/10.1186\/s40779-023-00445-z.","journal-title":"Mil Med Res"},{"issue":"12","key":"600_CR175","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1021\/acs.molpharmaceut.3c00956","volume":"20","author":"AG Reinhart","year":"2023","unstructured":"Reinhart AG, Osterwald A, Ringler P, Leiser Y, Lauer ME, Martin RE, et al. Investigations into mRNA lipid nanoparticles shelf-life stability under nonfrozen conditions. Mol Pharm. 2023;20(12):6492\u2013503. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00956.","journal-title":"Mol Pharm"},{"key":"600_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102174","volume":"61","author":"A Gouda","year":"2021","unstructured":"Gouda A, Sakr OS, Nasr M, Sammour O. Ethanol injection technique for liposomes formulation: an insight into development, influencing factors, challenges and applications. J Drug Deliv Sci Technol. 2021;61:102174. https:\/\/doi.org\/10.1016\/j.jddst.2020.102174.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"600_CR177","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/17425247.2022.2135502","volume":"19","author":"C Lopes","year":"2022","unstructured":"Lopes C, Crist\u00f3v\u00e3o J, Silv\u00e9rio V, Lino PR, Fonte P. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. Expert Opin Drug Deliv. 2022;19(10):1381\u201395. https:\/\/doi.org\/10.1080\/17425247.2022.2135502.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"600_CR178","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1021\/acs.molpharmaceut.6b00158","volume":"13","author":"JB Du","year":"2016","unstructured":"Du JB, Cheng Y, Teng ZH, Huan ML, Liu M, Cui H, et al. pH-triggered surface charge reversed nanoparticle with active targeting to enhance the antitumor activity of doxorubicin. Mol Pharm. 2016;13(5):1711\u201322. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00158.","journal-title":"Mol Pharm"},{"issue":"4","key":"600_CR179","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1248\/bpb.b21-01016","volume":"45","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Aihara K, Ishida T. Importance of process parameters influencing the mean diameters of siRNA-containing Lipid Nanoparticles (LNPs) on the in vitro activity of prepared LNPs. Biol Pharm Bull. 2022;45(4):497\u2013507. https:\/\/doi.org\/10.1248\/bpb.b21-01016.","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"600_CR180","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1021\/acsabm.1c00732","volume":"6","author":"MS Ali","year":"2023","unstructured":"Ali MS, Hooshmand N, El-Sayed M, Labouta HI. Microfluidics for development of lipid nanoparticles: paving the way for nucleic acids to the clinic. ACS Appl Bio Mater. 2023;6(9):3566\u201376. https:\/\/doi.org\/10.1021\/acsabm.1c00732.","journal-title":"ACS Appl Bio Mater"},{"issue":"9","key":"600_CR181","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202105832","volume":"18","author":"L Cui","year":"2022","unstructured":"Cui L, Hunter MR, Sonzini S, Pereira S, Romanelli SM, Liu K, et al. Mechanistic studies of an automated lipid nanoparticle reveal critical pharmaceutical properties associated with enhanced mRNA functional delivery in vitro and in vivo. Small. 2022;18(9):e2105832. https:\/\/doi.org\/10.1002\/smll.202105832.","journal-title":"Small"},{"issue":"42","key":"600_CR182","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","volume":"40","author":"JM Carre\u00f1o","year":"2022","unstructured":"Carre\u00f1o JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine. 2022;40(42):6114\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.024.","journal-title":"Vaccine"},{"issue":"2","key":"600_CR183","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/vaccines12020169","volume":"12","author":"X Tong","year":"2024","unstructured":"Tong X, Raffaele J, Feller K, Dornadula G, Devlin J, Boyd D, et al. Correlating stability-indicating biochemical and biophysical characteristics with in vitro cell potency in mRNA LNP vaccine. Vaccines (Basel). 2024;12(2):169. https:\/\/doi.org\/10.3390\/vaccines12020169.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"600_CR184","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271-1283.e16. https:\/\/doi.org\/10.1016\/j.cell.2020.07.024.","journal-title":"Cell"},{"issue":"11","key":"600_CR185","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41565-024-01765-4","volume":"19","author":"S Zhao","year":"2024","unstructured":"Zhao S, Gao K, Han H, Stenzel M, Yin B, Song H, et al. Acid-degradable lipid nanoparticles enhance the delivery of mRNA. Nat Nanotechnol. 2024;19(11):1702\u201311. https:\/\/doi.org\/10.1038\/s41565-024-01765-4.","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"600_CR186","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1021\/acs.molpharmaceut.2c00092","volume":"19","author":"M Kloczewiak","year":"2022","unstructured":"Kloczewiak M, Banks JM, Jin L, Brader ML. A biopharmaceutical perspective on higher-order structure and thermal stability of mRNA vaccines. Mol Pharm. 2022;19(7):2022\u201331. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00092.","journal-title":"Mol Pharm"},{"issue":"11","key":"600_CR187","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3390\/pharmaceutics14112357","volume":"14","author":"M Kamiya","year":"2022","unstructured":"Kamiya M, Matsumoto M, Yamashita K, Izumi T, Kawaguchi M, Mizukami S, et al. Stability study of mRNA-lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability. Pharmaceutics. 2022;14(11):2357. https:\/\/doi.org\/10.3390\/pharmaceutics14112357.","journal-title":"Pharmaceutics"},{"issue":"1","key":"600_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/bmjos-2021-100203","volume":"5","author":"L Kudsiova","year":"2021","unstructured":"Kudsiova L, Lansley A, Scutt G, Allen M, Bowler L, Williams S, et al. Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres. BMJ Open Sci. 2021;5(1):e100203. https:\/\/doi.org\/10.1136\/bmjos-2021-100203.","journal-title":"BMJ Open Sci"},{"issue":"Pt 2","key":"600_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114370","volume":"388","author":"E Reus","year":"2025","unstructured":"Reus E, Savinsky J, Wennemaring S, K\u00e4sbach J, Kerkhoffs F, Kehrein J, et al. Self-regulating microfluidic system for lipid nanoparticle production. J Control Release. 2025;388(Pt 2):114370. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114370.","journal-title":"J Control Release"},{"key":"600_CR190","doi-asserted-by":"publisher","DOI":"10.3791\/67047","volume":"210","author":"SN Subraveti","year":"2024","unstructured":"Subraveti SN, Wilson BK, Bizmark N, Liu J, Prud\u2019homme RK. Synthesizing lipid nanoparticles by turbulent flow in confined impinging jet mixers. J Vis Exp. 2024;210:e67047. https:\/\/doi.org\/10.3791\/67047.","journal-title":"J Vis Exp"},{"issue":"4","key":"600_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041141","volume":"15","author":"M Tang","year":"2023","unstructured":"Tang M, Sagawa A, Inoue N, Torii S, Tomita K, Hattori Y. Efficient mRNA delivery with mRNA lipoplexes prepared using a modified ethanol injection method. Pharmaceutics. 2023;15(4):1141. https:\/\/doi.org\/10.3390\/pharmaceutics15041141.","journal-title":"Pharmaceutics"},{"issue":"11","key":"600_CR192","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.1021\/acsabm.4c01176","volume":"7","author":"B Kim","year":"2024","unstructured":"Kim B, Subraveti SN, Liu JX, Nayagam SK, Merghoub S, Caggiano NJ, et al. Diblock copolymer targeted lipid nanoparticles: next-generation nucleic acid delivery system produced by confined impinging jet mixers. ACS Appl Bio Mater. 2024;7(11):7595\u2013607. https:\/\/doi.org\/10.1021\/acsabm.4c01176.","journal-title":"ACS Appl Bio Mater"},{"key":"600_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2023.100161","volume":"12","author":"DC J\u00fcrgens","year":"2023","unstructured":"J\u00fcrgens DC, De\u00dfloch L, Porras-Gonzalez D, Winkeljann J, Zielinski S, Munschauer M, et al. Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques - an evaluation of particle properties and efficiency. OpenNano. 2023;12:100161. https:\/\/doi.org\/10.1016\/j.onano.2023.100161.","journal-title":"OpenNano"},{"key":"600_CR194","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","volume":"344","author":"M Maeki","year":"2022","unstructured":"Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release. 2022;344:80\u201396. https:\/\/doi.org\/10.1016\/j.jconrel.2022.02.017.","journal-title":"J Control Release"},{"key":"600_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586.","journal-title":"Int J Pharm"},{"key":"600_CR196","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","volume":"353","author":"B Kim","year":"2023","unstructured":"Kim B, Hosn RR, Remba T, Yun D, Li N, Abraham W, et al. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. J Control Release. 2023;353:241\u201353. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.022.","journal-title":"J Control Release"},{"issue":"1","key":"600_CR197","doi-asserted-by":"publisher","first-page":"2200071","DOI":"10.1002\/smsc.202200071","volume":"3","author":"K Hashiba","year":"2023","unstructured":"Hashiba K, Sato Y, Taguchi M, Sakamoto S, Otsu A, Maeda Y, et al. Branching ionizable lipids can enhance the stability, fusogenicity, and functional delivery of mRNA. Small Sci. 2023;3(1):2200071. https:\/\/doi.org\/10.1002\/smsc.202200071.","journal-title":"Small Sci"},{"key":"600_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124005","volume":"1234","author":"RE Birdsall","year":"2024","unstructured":"Birdsall RE, Han D, DeLaney K, Kowalczyk A, Cojocaru R, Lauber M, et al. Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1234:124005. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124005.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"17","key":"600_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202206968","volume":"19","author":"AM J\u00f6rgensen","year":"2023","unstructured":"J\u00f6rgensen AM, Wibel R, Bernkop-Schn\u00fcrch A. Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients. Small. 2023;19(17):e2206968. https:\/\/doi.org\/10.1002\/smll.202206968.","journal-title":"Small"},{"issue":"31","key":"600_CR200","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303370","volume":"35","author":"MHY Cheng","year":"2023","unstructured":"Cheng MHY, Leung J, Zhang Y, Strong C, Basha G, Momeni A, et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv Mater. 2023;35(31):e2303370. https:\/\/doi.org\/10.1002\/adma.202303370.","journal-title":"Adv Mater"},{"key":"600_CR201","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jconrel.2024.07.046","volume":"373","author":"JB Simonsen","year":"2024","unstructured":"Simonsen JB. A perspective on bleb and empty LNP structures. J Control Release. 2024;373:952\u201361. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.046.","journal-title":"J Control Release"},{"key":"600_CR202","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jconrel.2022.11.037","volume":"353","author":"AJ Da Silva Sanchez","year":"2023","unstructured":"Da Silva Sanchez AJ, Zhao K, Huayamares SG, Hatit MZC, Lokugamage MP, Loughrey D, et al. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. J Control Release. 2023;353:270\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.037.","journal-title":"J Control Release"},{"issue":"1","key":"600_CR203","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15(1):6305. https:\/\/doi.org\/10.1038\/s41467-024-50619-z.","journal-title":"Nat Commun"},{"issue":"3","key":"600_CR204","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.xphs.2021.11.004","volume":"111","author":"NR Larson","year":"2022","unstructured":"Larson NR, Hu G, Wei Y, Tuesca AD, Forrest ML, Middaugh CR. pH-dependent phase behavior and stability of cationic lipid-mRNA nanoparticles. J Pharm Sci. 2022;111(3):690\u20138. https:\/\/doi.org\/10.1016\/j.xphs.2021.11.004.","journal-title":"J Pharm Sci"},{"issue":"20","key":"600_CR205","doi-asserted-by":"publisher","first-page":"11254","DOI":"10.3390\/ijms252011254","volume":"25","author":"I Rivero Berti","year":"2024","unstructured":"Rivero Berti I, Gambaro RC, Limeres MJ, Huck-Iriart C, Svensson M, Fraude-El Ghazi S, et al. Encapsulation of dexamethasone into mRNA-lipid nanoparticles is a promising approach for the development of liver-targeted anti-inflammatory therapies. Int J Mol Sci. 2024;25(20):11254. https:\/\/doi.org\/10.3390\/ijms252011254.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"600_CR206","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303857","volume":"13","author":"O Jung","year":"2024","unstructured":"Jung O, Jung HY, Thuy LT, Choi M, Kim S, Jeon HG, et al. Modulating lipid nanoparticles with histidinamide-conjugated cholesterol for improved intracellular delivery of mRNA. Adv Healthc Mater. 2024;13(14):e2303857. https:\/\/doi.org\/10.1002\/adhm.202303857.","journal-title":"Adv Healthc Mater"},{"issue":"2","key":"600_CR207","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/pharmaceutics14020430","volume":"14","author":"Z Kis","year":"2022","unstructured":"Kis Z. Stability modelling of mRNA vaccine quality based on temperature monitoring throughout the distribution chain. Pharmaceutics. 2022;14(2):430. https:\/\/doi.org\/10.3390\/pharmaceutics14020430.","journal-title":"Pharmaceutics"},{"issue":"1","key":"600_CR208","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5539\/jmbr.v6n1p52","volume":"6","author":"M Khosravifarsani","year":"2016","unstructured":"Khosravifarsani M, Shabestani-Monfared A, Pouramir M, Zabihi E. Hydroxyl radical (\u00baOH) scavenger power of Tris (hydroxymethyl) compared to phosphate buffer. J Mol Biol Res. 2016;6(1):52. https:\/\/doi.org\/10.5539\/jmbr.v6n1p52.","journal-title":"J Mol Biol Res"},{"issue":"11","key":"600_CR209","doi-asserted-by":"publisher","first-page":"10829","DOI":"10.1021\/acsnano.4c14098","volume":"19","author":"C Carucci","year":"2025","unstructured":"Carucci C, Philipp J, M\u00fcller JA, Sudarsan A, Kostyurina E, Blanchet CE, et al. Buffer specificity of ionizable lipid nanoparticle transfection efficiency and bulk phase transition. ACS Nano. 2025;19(11):10829\u201340. https:\/\/doi.org\/10.1021\/acsnano.4c14098.","journal-title":"ACS Nano"},{"issue":"1","key":"600_CR210","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12951-025-03318-w","volume":"23","author":"S Tang","year":"2025","unstructured":"Tang S, Huang L, Ge J, Li J, Qiu M, Zhang Y, et al. Influence of salt solution on the physicochemical properties and in vitro\/in vivo expression of mRNA\/LNP. J Nanobiotechnology. 2025;23(1):223. https:\/\/doi.org\/10.1186\/s12951-025-03318-w.","journal-title":"J Nanobiotechnology"},{"issue":"11","key":"600_CR211","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1021\/acs.molpharmaceut.2c00587","volume":"19","author":"MI Henderson","year":"2022","unstructured":"Henderson MI, Eygeris Y, Jozic A, Herrera M, Sahay G. Leveraging biological buffers for efficient messenger RNA delivery via lipid nanoparticles. Mol Pharm. 2022;19(11):4275\u201385. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00587.","journal-title":"Mol Pharm"},{"key":"600_CR212","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124696","volume":"665","author":"H Athaydes Seabra Ferreira","year":"2024","unstructured":"Athaydes Seabra Ferreira H, Ricardo Aluotto Scalzo J\u00fanior S, Kelton Santos de Faria K, Henrique Costa Silva G, T\u00fallio Rodrigues Alves M, Oliveira Lobo A, et al. Cryoprotectant optimization for enhanced stability and transfection efficiency of pDNA-loaded ionizable lipid nanoparticles. Int J Pharm. 2024;665:124696. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124696.","journal-title":"Int J Pharm"},{"issue":"3","key":"600_CR213","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","volume":"142","author":"C Chen","year":"2010","unstructured":"Chen C, Han D, Cai C, Tang X. An overview of liposome lyophilization and its future potential. J Control Release. 2010;142(3):299\u2013311. https:\/\/doi.org\/10.1016\/j.jconrel.2009.10.024.","journal-title":"J Control Release"},{"issue":"3","key":"600_CR214","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/pharmaceutics10030139","volume":"10","author":"S Franz\u00e9","year":"2018","unstructured":"Franz\u00e9 S, Selmin F, Samaritani E, Minghetti P, Cilurzo F. Lyophilization of liposomal formulations: still necessary, still challenging. Pharmaceutics. 2018;10(3):139. https:\/\/doi.org\/10.3390\/pharmaceutics10030139.","journal-title":"Pharmaceutics"},{"issue":"18","key":"600_CR215","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202203022","volume":"12","author":"KN Kafetzis","year":"2023","unstructured":"Kafetzis KN, Papalamprou N, McNulty E, Thong KX, Sato Y, Mironov A, et al. The effect of cryoprotectants and storage conditions on the transfection efficiency, stability, and safety of lipid-based nanoparticles for mRNA and DNA delivery. Adv Healthc Mater. 2023;12(18):e2203022. https:\/\/doi.org\/10.1002\/adhm.202203022.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"600_CR216","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/acsnano.2c10501","volume":"17","author":"H Tanaka","year":"2023","unstructured":"Tanaka H, Hagiwara S, Shirane D, Yamakawa T, Sato Y, Matsumoto C, et al. Ready-to-use-type lyophilized lipid nanoparticle formulation for the postencapsulation of messenger RNA. ACS Nano. 2023;17(3):2588\u2013601. https:\/\/doi.org\/10.1021\/acsnano.2c10501.","journal-title":"ACS Nano"},{"key":"600_CR217","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fchem.2018.00004","volume":"6","author":"J Horn","year":"2018","unstructured":"Horn J, Friess W. Detection of collapse and crystallization of saccharide, protein, and mannitol formulations by optical fibers in lyophilization. Front Chem. 2018;6:4. https:\/\/doi.org\/10.3389\/fchem.2018.00004.","journal-title":"Front Chem"},{"issue":"8","key":"600_CR218","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1248\/bpb.b18-00208","volume":"41","author":"D Shirane","year":"2018","unstructured":"Shirane D, Tanaka H, Nakai Y, Yoshioka H, Akita H. Development of an alcohol dilution-lyophilization method for preparing lipid nanoparticles containing encapsulated siRNA. Biol Pharm Bull. 2018;41(8):1291\u20134. https:\/\/doi.org\/10.1248\/bpb.b18-00208.","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"600_CR219","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1039\/D2BM02031A","volume":"11","author":"A Lamoot","year":"2023","unstructured":"Lamoot A, Lammens J, De Lombaerde E, Zhong Z, Gontsarik M, Chen Y, et al. Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids. Biomater Sci. 2023;11(12):4327\u201334. https:\/\/doi.org\/10.1039\/D2BM02031A.","journal-title":"Biomater Sci"},{"issue":"6","key":"600_CR220","doi-asserted-by":"publisher","first-page":"2400537","DOI":"10.1002\/adtp.202400537","volume":"8","author":"JA Choe","year":"2025","unstructured":"Choe JA, Burger J, Jones J, Panjla A, Murphy WL. Opportunities in therapeutic mRNA stabilization: sequence, structure, adjuvants and vectors. Adv Ther (Weinh). 2025;8(6):2400537. https:\/\/doi.org\/10.1002\/adtp.202400537.","journal-title":"Adv Ther (Weinh)"},{"issue":"2","key":"600_CR221","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1021\/acs.molpharmaceut.4c01239","volume":"22","author":"SJ Feng","year":"2025","unstructured":"Feng SJ, Chu GW, Li H, Chen JF. Atomic insights into pH-dependent and water permeation of mRNA-lipid nanoparticles. Mol Pharm. 2025;22(2):1020\u201330. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01239.","journal-title":"Mol Pharm"},{"issue":"5","key":"600_CR222","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","volume":"12","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano. 2018;12(5):4787\u201395. https:\/\/doi.org\/10.1021\/acsnano.8b01516.","journal-title":"ACS Nano"},{"issue":"25","key":"600_CR223","doi-asserted-by":"publisher","first-page":"17972","DOI":"10.1021\/acsnano.5c22170","volume":"20","author":"M Mohammadi-Zerankeshi","year":"2026","unstructured":"Mohammadi-Zerankeshi M, Charland DJ, Donnelly KA, Nash GT, Shi J, Patil DN, et al. Storage buffer composition impacts internal structure, freeze-thaw stability, and transfection efficiency of mRNA-lipid nanoparticles. ACS Nano. 2026;20(25):17972\u201387. https:\/\/doi.org\/10.1021\/acsnano.5c22170.","journal-title":"ACS Nano"},{"issue":"10","key":"600_CR224","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","volume":"198","author":"T Pepini","year":"2017","unstructured":"Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol. 2017;198(10):4012\u201324. https:\/\/doi.org\/10.4049\/jimmunol.1601877.","journal-title":"J Immunol"},{"issue":"5","key":"600_CR225","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2024.03.022","volume":"32","author":"S Abbasi","year":"2024","unstructured":"Abbasi S, Matsui-Masai M, Yasui F, Hayashi A, Tockary TA, Mochida Y, et al. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol Ther. 2024;32(5):1266\u201383. https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.022.","journal-title":"Mol Ther"},{"issue":"30","key":"600_CR226","doi-asserted-by":"publisher","first-page":"27977","DOI":"10.1021\/acsnano.5c10648","volume":"19","author":"Y Kawaguchi","year":"2025","unstructured":"Kawaguchi Y, Kimura M, Karaki T, Tanaka H, Ono C, Ishida T, et al. Modulating immunogenicity and reactogenicity in mRNA-lipid nanoparticle vaccines through lipid component optimization. ACS Nano. 2025;19(30):27977\u20138001. https:\/\/doi.org\/10.1021\/acsnano.5c10648.","journal-title":"ACS Nano"},{"key":"600_CR227","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","volume":"266","author":"Y Sato","year":"2017","unstructured":"Sato Y, Matsui H, Yamamoto N, Sato R, Munakata T, Kohara M, et al. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus. J Control Release. 2017;266:216\u201325. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.044.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"600_CR228","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","volume":"354","author":"T Ishida","year":"2008","unstructured":"Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008;354(1\u20132):56\u201362. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.11.005.","journal-title":"Int J Pharm"},{"issue":"1","key":"600_CR229","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41565-024-01747-6","volume":"20","author":"L Xue","year":"2025","unstructured":"Xue L, Zhao G, Gong N, Han X, Shepherd SJ, Xiong X, et al. Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery. Nat Nanotechnol. 2025;20(1):132\u201343. https:\/\/doi.org\/10.1038\/s41565-024-01747-6.","journal-title":"Nat Nanotechnol"},{"key":"600_CR230","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41551-023-01082-6","volume":"9","author":"B Li","year":"2025","unstructured":"Li B, Jiang AY, Raji I, Atyeo C, Raimondo TM, Gordon AGR, et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nat Biomed Eng. 2025;9(2):167\u201384. https:\/\/doi.org\/10.1038\/s41551-023-01082-6.","journal-title":"Nat Biomed Eng"},{"issue":"49","key":"600_CR231","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1021\/acs.nanolett.5c04371","volume":"25","author":"R Wang","year":"2025","unstructured":"Wang R, Bao L, Yu Y, Zhang R, Guo Z, Kubiatowicz LJ, et al. Bacterial membrane coating potentiates lipid nanoparticles for mRNA delivery. Nano Lett. 2025;25(49):17074\u201381. https:\/\/doi.org\/10.1021\/acs.nanolett.5c04371.","journal-title":"Nano Lett"},{"issue":"9","key":"600_CR232","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41565-025-01958-5","volume":"20","author":"M Vadovics","year":"2025","unstructured":"Vadovics M, Zhao W, Daley EF, Lam K, Daly O, Rashid K, et al. Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications. Nat Nanotechnol. 2025;20(9):1312\u201322. https:\/\/doi.org\/10.1038\/s41565-025-01958-5.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"600_CR233","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ymthe.2021.01.030","volume":"29","author":"SM Moghimi","year":"2021","unstructured":"Moghimi SM. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines. Mol Ther. 2021;29(3):898\u2013900. https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.030.","journal-title":"Mol Ther"},{"issue":"20","key":"600_CR234","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1016\/j.bpj.2022.08.037","volume":"121","author":"MFW Trollmann","year":"2022","unstructured":"Trollmann MFW, B\u00f6ckmann RA. mRNA lipid nanoparticle phase transition. Biophys J. 2022;121(20):3927\u201339. https:\/\/doi.org\/10.1016\/j.bpj.2022.08.037.","journal-title":"Biophys J"},{"key":"600_CR235","doi-asserted-by":"publisher","unstructured":"Silambarasan I, Rajalakshmi AN. A review on freeze-drying: a stability enhancement technique. Res J Pharm Technol. 2022;15(10):4841\u20134846. https:\/\/doi.org\/10.52711\/0974-360X.2022.00813.","DOI":"10.52711\/0974-360X.2022.00813"},{"issue":"5","key":"600_CR236","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","volume":"30","author":"H Muramatsu","year":"2022","unstructured":"Muramatsu H, Lam K, Bajusz C, Laczk\u00f3 D, Karik\u00f3 K, Schreiner P, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.001.","journal-title":"Mol Ther"},{"issue":"1","key":"600_CR237","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","volume":"9","author":"L Ai","year":"2023","unstructured":"Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9(1):9. https:\/\/doi.org\/10.1038\/s41421-022-00517-9.","journal-title":"Cell Discov"},{"issue":"12","key":"600_CR238","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s42256-022-00571-8","volume":"4","author":"HK Wayment-Steele","year":"2022","unstructured":"Wayment-Steele HK, Kladwang W, Watkins AM, Kim DS, Tunguz B, Reade W, et al. Deep learning models for predicting RNA degradation via dual crowdsourcing. Nat Mach Intell. 2022;4(12):1174\u201384. https:\/\/doi.org\/10.1038\/s42256-022-00571-8.","journal-title":"Nat Mach Intell"},{"issue":"7978","key":"600_CR239","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396\u2013403. https:\/\/doi.org\/10.1038\/s41586-023-06127-z.","journal-title":"Nature"},{"issue":"48","key":"600_CR240","doi-asserted-by":"publisher","first-page":"24075","DOI":"10.1073\/pnas.1908052116","volume":"116","author":"DM Mauger","year":"2019","unstructured":"Mauger DM, Cabral BJ, Presnyak V, Su SV, Reid DW, Goodman B, et al. mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci U S A. 2019;116(48):24075\u201383. https:\/\/doi.org\/10.1073\/pnas.1908052116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"600_CR241","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101327","volume":"17","author":"J Szebeni","year":"2025","unstructured":"Szebeni J. Unique features and collateral immune effects of mRNA-LNP COVID-19 vaccines: plausible mechanisms of adverse events and complications. Pharmaceutics. 2025;17(10):1327. https:\/\/doi.org\/10.3390\/pharmaceutics17101327.","journal-title":"Pharmaceutics"},{"issue":"5","key":"600_CR242","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/v15051120","volume":"15","author":"N Rcheulishvili","year":"2023","unstructured":"Rcheulishvili N, Mao J, Papukashvili D, Feng S, Liu C, Yang X, et al. Development of a multi-epitope universal mRNA vaccine candidate for monkeypox, smallpox, and vaccinia viruses: design and in silico analyses. Viruses. 2023;15(5):1120. https:\/\/doi.org\/10.3390\/v15051120.","journal-title":"Viruses"},{"issue":"52","key":"600_CR243","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci U S A. 2021;118(52):e2109256118. https:\/\/doi.org\/10.1073\/pnas.2109256118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"600_CR244","doi-asserted-by":"publisher","first-page":"1501010","DOI":"10.3389\/fcimb.2024.1501010","volume":"14","author":"S Imani","year":"2025","unstructured":"Imani S, Li X, Chen K, Maghsoudloo M, Jabbarzadeh Kaboli P, Hashemi M, et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front Cell Infect Microbiol. 2025;14:1501010. https:\/\/doi.org\/10.3389\/fcimb.2024.1501010.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"600_CR245","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.it.2023.03.002","volume":"44","author":"AP Hederman","year":"2023","unstructured":"Hederman AP, Ackerman ME. Leveraging deep learning to improve vaccine design. Trends Immunol. 2023;44(5):333\u201344. https:\/\/doi.org\/10.1016\/j.it.2023.03.002.","journal-title":"Trends Immunol"},{"issue":"7","key":"600_CR246","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B Li","year":"2024","unstructured":"Li B, Raji IO, Gordon AGR, Sun L, Raimondo TM, Oladimeji FA, et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat Mater. 2024;23(7):1002\u20138. https:\/\/doi.org\/10.1038\/s41563-024-01867-3.","journal-title":"Nat Mater"},{"issue":"1","key":"600_CR247","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Chen K, Jiang T, Wu Y, Wu Z, Ying H, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nat Commun. 2024;15(1):10804. https:\/\/doi.org\/10.1038\/s41467-024-55072-6.","journal-title":"Nat Commun"},{"issue":"12","key":"600_CR248","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1039\/D4CS00891J","volume":"54","author":"Z Liu","year":"2025","unstructured":"Liu Z, Chen J, Xu M, Ho S, Wei Y, Ho HP, et al. Engineered multi-domain lipid nanoparticles for targeted delivery. Chem Soc Rev. 2025;54(12):5961\u201394. https:\/\/doi.org\/10.1039\/D4CS00891J.","journal-title":"Chem Soc Rev"},{"issue":"12","key":"600_CR249","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1021\/acsabm.1c00932","volume":"4","author":"M Rahimnejad","year":"2021","unstructured":"Rahimnejad M, Rabiee N, Ahmadi S, Jahangiri S, Sajadi SM, Akhavan O, et al. Emerging phospholipid nanobiomaterials for biomedical applications to Lab-on-a-Chip, drug delivery, and cellular engineering. ACS Appl Bio Mater. 2021;4(12):8110\u201328. https:\/\/doi.org\/10.1021\/acsabm.1c00932.","journal-title":"ACS Appl Bio Mater"},{"issue":"13","key":"600_CR250","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/0008-5472.CAN-24-2553","volume":"85","author":"J Zeng","year":"2025","unstructured":"Zeng J, Lin Z, Zhang X, Zheng T, Xu H, Liu T. Leveraging artificial intelligence for neoantigen prediction. Cancer Res. 2025;85(13):2376\u201387. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2553.","journal-title":"Cancer Res"},{"issue":"2","key":"600_CR251","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.apsb.2025.11.029","volume":"16","author":"K Su","year":"2026","unstructured":"Su K, Qiu J, Xu T, Liu S. Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery. Acta Pharm Sin B. 2026;16(2):709\u201327. https:\/\/doi.org\/10.1016\/j.apsb.2025.11.029.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"600_CR252","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01073-2","volume":"27","author":"B Misra","year":"2025","unstructured":"Misra B, Hughes KA, Pentz WH, Surface M, Geldenhuys WJ, Bobbala S. TLR7-adjuvanted ionizable lipid nanoparticles for mRNA vaccine delivery. AAPS J. 2025;27(4):80. https:\/\/doi.org\/10.1208\/s12248-025-01073-2.","journal-title":"AAPS J"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00600-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:05:16Z","timestamp":1790712316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":252,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00600-7","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"186"}}